血管抑制剂
阿柏西普
贝伐单抗
血管内皮生长因子
医学
眼科
视网膜
脉络膜新生血管
血管通透性
血管内皮生长因子受体
内科学
化疗
作者
Naoya Yoshihara,Hiroto Terasaki,Makoto Shirasawa,Hiroki Kawano,Shozo Sonoda,Munekazu Yamaguchi,Teruto Hashiguchi,Toshio Hisatomi,Tatsuro Ishibashi,Taiji Sakamoto
标识
DOI:10.1097/iae.0000000000001117
摘要
The greater reduction of the amount of VEGF in the lower chamber by aflibercept and ranibizumab than bevacizumab may explain why aflibercept and ranibizumab are more effective than bevacizumab against type 1 choroidal neovascularization.
科研通智能强力驱动
Strongly Powered by AbleSci AI